Clinical trials for Breast cancer

235 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer #NCT06298084 #2023-505925-15-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 1 Breast cancer Lung cancer Colon cancer Rectal cancer Pancreas cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Cervical / Vulvar / Vaginal cancer #NCT06400472 #2024-511238-11-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Cervical cancer
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT07403721
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Amgen
Phase 1 Breast cancer Lung cancer Prostate cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT07156136
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Immunocore Ltée
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07695831
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Car-T Bispecific T-cell engager antibodies
1 recruiting site
Genmab
Phase 1 Breast cancer #NCT06120283 #2023-506888-34-00
Phase 1b Cohorte d'expansion 1
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
BeOne Medecines
Phase 1 Breast cancer #NCT06120283 #2023-506888-34-00
Phase 1b Cohortes d'expansion 2 et 3
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
7 recruiting sites
BeOne Medecines
Phase 1 Breast cancer Lung cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06120283 #2023-506888-34-00
Phase 1a Escalade de dose
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Epithelial ovarian cancer
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
BeOne Medecines
Phase 1 Breast cancer #NCT06120283 #2023-506888-34-00
Phase 1a Extension de sécurité
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2 3 or more
7 recruiting sites
BeOne Medecines